_id

690dadccccc777a4e85d0a3c

Ticker

ALXO

Name

Alx Oncology Holdings 

Exchange

NASDAQ

Address

323 Allerton Avenue, South San Francisco, CA, United States, 94080

Country

USA

Sector

Healthcare

Industry

Biotechnology

Currency

USD

Website

https://www.alxoncology.com

Description

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Last Close

1.52

Volume

143660

Current Price

1.47

Change

-3.2894736842105288

Last Updated

2025-11-28T12:09:27.747Z

Image

data:image/webp;base64,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

Ipo Date

2020-07-17T00:00:00.000Z

Market Cap

74820840

Next Dividend Date

-

Dividend Frequency

-

Dividend Rate

-

Dividend Yield

0

Sentiment

-0.11966666666666666

Sentiment Sources

3

Rating

4.3333

Target Price

3

Strong Buy

3

Buy

2

Hold

1

Sell

0

Strong Sell

0

Current Quarter

2025-09-30

Revenue

0

Cost Of Revenue

-

Gross Profit

-

Operating Expenses

22532000

Operating Income

-22532000

Interest Expense

408000

Pretax Income

-22144000

Net Income

-22144000

Eps

-0.41331117310529847

Dividends Per Share

-

Shares Outstanding

54218001

Income Tax Expense

-

EBITDA

-21583000

Operating Margin

-

Total Other Income Expense Net

388000

Cash

23442000

Short Term Investments

37184000

Receivables

-

Inventories

-

Total Current Assets

66516000

Property Plant Equipment

1351000

Total Assets

82723000

Payables

6583000

Short Term Debt

4348000

Long Term Debt

5764000

Total Liabilities

37923000

Equity

44800000

Depreciation

153000

Change In Working Capital

2124000

Cash From Operations

-17093000

Capital Expenditures

56000

Cash From Investing

21392000

Cash From Financing

-159000

Net Change In Cash

4140000

PE

-

PB

1.757997478125

ROE

-49.42857142857143

ROA

-26.768855094713683

FCF

-17149000

Fcf Percent

-

Piotroski FScore

1

Health Score

39

Deep Value Investing Score

3

Defensive Investing Score

6.5

Dividend Investing Score

1.5

Economic Moat Investing Score

3.3

Garp Investing Score

1.5

Growth Investing Score

0.5

Momentum Investing Score

2

Net Net Investing Score

1.5

Quality Investing Score

2

Value Investing Score

4

Quarters > 0 > quarter

2025-09-30

Quarters > 0 > income Statement > revenue

0

Quarters > 0 > income Statement > cost Of Revenue

-

Quarters > 0 > income Statement > gross Profit

-

Quarters > 0 > income Statement > operating Expenses

22532000

Quarters > 0 > income Statement > operating Income

-22532000

Quarters > 0 > income Statement > interest Expense

408000

Quarters > 0 > income Statement > pretax Income

-22144000

Quarters > 0 > income Statement > net Income

-22144000

Quarters > 0 > income Statement > eps

-0.41331117310529847

Quarters > 0 > income Statement > dividends Per Share

-

Quarters > 0 > income Statement > shares Outstanding

53577066

Quarters > 0 > income Statement > income Tax Expense

-

Quarters > 0 > income Statement > EBITDA

-21583000

Quarters > 0 > income Statement > operating Margin

-

Quarters > 0 > income Statement > total Other Income Expense Net

388000

Quarters > 0 > balance Sheet > cash

23442000

Quarters > 0 > balance Sheet > short Term Investments

37184000

Quarters > 0 > balance Sheet > receivables

-

Quarters > 0 > balance Sheet > inventories

-

Quarters > 0 > balance Sheet > total Current Assets

66516000

Quarters > 0 > balance Sheet > property Plant Equipment

1351000

Quarters > 0 > balance Sheet > total Assets

82723000

Quarters > 0 > balance Sheet > payables

6583000

Quarters > 0 > balance Sheet > short Term Debt

4348000

Quarters > 0 > balance Sheet > long Term Debt

5764000

Quarters > 0 > balance Sheet > total Liabilities

37923000

Quarters > 0 > balance Sheet > equity

44800000

Quarters > 0 > cash Flow > net Income

-22144000

Quarters > 0 > cash Flow > depreciation

153000

Quarters > 0 > cash Flow > change In Working Capital

2124000

Quarters > 0 > cash Flow > cash From Operations

-17093000

Quarters > 0 > cash Flow > capital Expenditures

56000

Quarters > 0 > cash Flow > cash From Investing

21392000

Quarters > 0 > cash Flow > cash From Financing

-159000

Quarters > 0 > cash Flow > net Change In Cash

4140000

Quarters > 0 > ratios > PE

-0.41331117310529847

Quarters > 0 > ratios > PB

1.757997478125

Quarters > 0 > ratios > ROE

-49.42857142857143

Quarters > 0 > ratios > ROA

-26.768855094713683

Quarters > 0 > ratios > FCF

-17149000

Quarters > 0 > ratios > Piotroski FScore

1

Quarters > 0 > ratios > fcf Percent

-

Quarters > 0 > health Score

39

Quarters > 1 > quarter

2025-06-30

Quarters > 1 > income Statement > revenue

0

Quarters > 1 > income Statement > cost Of Revenue

191000

Quarters > 1 > income Statement > gross Profit

-191000

Quarters > 1 > income Statement > operating Expenses

26648000

Quarters > 1 > income Statement > operating Income

-26648000

Quarters > 1 > income Statement > interest Expense

405000

Quarters > 1 > income Statement > pretax Income

-25949000

Quarters > 1 > income Statement > net Income

-25949000

Quarters > 1 > income Statement > eps

-0.48552144514862217

Quarters > 1 > income Statement > dividends Per Share

-

Quarters > 1 > income Statement > shares Outstanding

53445631

Quarters > 1 > income Statement > income Tax Expense

-

Quarters > 1 > income Statement > EBITDA

-25353000

Quarters > 1 > income Statement > operating Margin

-

Quarters > 1 > income Statement > total Other Income Expense Net

699000

Quarters > 1 > balance Sheet > cash

19302000

Quarters > 1 > balance Sheet > short Term Investments

60012000

Quarters > 1 > balance Sheet > receivables

666000

Quarters > 1 > balance Sheet > inventories

-

Quarters > 1 > balance Sheet > total Current Assets

85257000

Quarters > 1 > balance Sheet > property Plant Equipment

1497000

Quarters > 1 > balance Sheet > total Assets

95320000

Quarters > 1 > balance Sheet > payables

4902000

Quarters > 1 > balance Sheet > short Term Debt

5050000

Quarters > 1 > balance Sheet > long Term Debt

6997000

Quarters > 1 > balance Sheet > total Liabilities

30905000

Quarters > 1 > balance Sheet > equity

64415000

Quarters > 1 > cash Flow > net Income

-25949000

Quarters > 1 > cash Flow > depreciation

191000

Quarters > 1 > cash Flow > change In Working Capital

-3172000

Quarters > 1 > cash Flow > cash From Operations

-23406000

Quarters > 1 > cash Flow > capital Expenditures

47000

Quarters > 1 > cash Flow > cash From Investing

22316000

Quarters > 1 > cash Flow > cash From Financing

-222000

Quarters > 1 > cash Flow > net Change In Cash

-1312000

Quarters > 1 > ratios > PE

-0.48552144514862217

Quarters > 1 > ratios > PB

1.2196705359000233

Quarters > 1 > ratios > ROE

-40.28409531941318

Quarters > 1 > ratios > ROA

-27.223038187159045

Quarters > 1 > ratios > FCF

-23453000

Quarters > 1 > ratios > Piotroski FScore

1

Quarters > 1 > ratios > fcf Percent

-

Quarters > 1 > health Score

43

Quarters > 2 > quarter

2025-03-31

Quarters > 2 > income Statement > revenue

0

Quarters > 2 > income Statement > cost Of Revenue

211000

Quarters > 2 > income Statement > gross Profit

-211000

Quarters > 2 > income Statement > operating Expenses

31820000

Quarters > 2 > income Statement > operating Income

-31820000

Quarters > 2 > income Statement > interest Expense

406000

Quarters > 2 > income Statement > pretax Income

-30754000

Quarters > 2 > income Statement > net Income

-30754000

Quarters > 2 > income Statement > eps

-0.5763564757868622

Quarters > 2 > income Statement > dividends Per Share

-

Quarters > 2 > income Statement > shares Outstanding

53359338

Quarters > 2 > income Statement > income Tax Expense

-

Quarters > 2 > income Statement > EBITDA

-30137000

Quarters > 2 > income Statement > operating Margin

-

Quarters > 2 > income Statement > total Other Income Expense Net

1066000

Quarters > 2 > balance Sheet > cash

20614000

Quarters > 2 > balance Sheet > short Term Investments

77217000

Quarters > 2 > balance Sheet > receivables

911000

Quarters > 2 > balance Sheet > inventories

-

Quarters > 2 > balance Sheet > total Current Assets

102532000

Quarters > 2 > balance Sheet > property Plant Equipment

8952000

Quarters > 2 > balance Sheet > total Assets

120900000

Quarters > 2 > balance Sheet > payables

3937000

Quarters > 2 > balance Sheet > short Term Debt

1739000

Quarters > 2 > balance Sheet > long Term Debt

8232000

Quarters > 2 > balance Sheet > total Liabilities

32605000

Quarters > 2 > balance Sheet > equity

88295000

Quarters > 2 > cash Flow > net Income

-30754000

Quarters > 2 > cash Flow > depreciation

211000

Quarters > 2 > cash Flow > change In Working Capital

645000

Quarters > 2 > cash Flow > cash From Operations

-24663000

Quarters > 2 > cash Flow > capital Expenditures

60000

Quarters > 2 > cash Flow > cash From Investing

27645000

Quarters > 2 > cash Flow > cash From Financing

65000

Quarters > 2 > cash Flow > net Change In Cash

3047000

Quarters > 2 > ratios > PE

-0.5763564757868622

Quarters > 2 > ratios > PB

0.8883654437963645

Quarters > 2 > ratios > ROE

-34.83096438076901

Quarters > 2 > ratios > ROA

-25.43755169561621

Quarters > 2 > ratios > FCF

-24723000

Quarters > 2 > ratios > Piotroski FScore

1

Quarters > 2 > ratios > fcf Percent

-

Quarters > 2 > health Score

42

Quarters > 3 > quarter

2024-12-31

Quarters > 3 > income Statement > revenue

868000

Quarters > 3 > income Statement > cost Of Revenue

-

Quarters > 3 > income Statement > gross Profit

434000

Quarters > 3 > income Statement > operating Expenses

30613000

Quarters > 3 > income Statement > operating Income

-30613000

Quarters > 3 > income Statement > interest Expense

427000

Quarters > 3 > income Statement > pretax Income

-29163000

Quarters > 3 > income Statement > net Income

-29163000

Quarters > 3 > income Statement > eps

-0.5523043465687333

Quarters > 3 > income Statement > dividends Per Share

-

Quarters > 3 > income Statement > shares Outstanding

52802409

Quarters > 3 > income Statement > income Tax Expense

-

Quarters > 3 > income Statement > EBITDA

-28522000

Quarters > 3 > income Statement > operating Margin

-3526.84331797235

Quarters > 3 > income Statement > total Other Income Expense Net

1450000

Quarters > 3 > balance Sheet > cash

17567000

Quarters > 3 > balance Sheet > short Term Investments

110190000

Quarters > 3 > balance Sheet > receivables

892000

Quarters > 3 > balance Sheet > inventories

-

Quarters > 3 > balance Sheet > total Current Assets

134352000

Quarters > 3 > balance Sheet > property Plant Equipment

9632000

Quarters > 3 > balance Sheet > total Assets

147775000

Quarters > 3 > balance Sheet > payables

4497000

Quarters > 3 > balance Sheet > short Term Debt

435000

Quarters > 3 > balance Sheet > long Term Debt

9469000

Quarters > 3 > balance Sheet > total Liabilities

34157000

Quarters > 3 > balance Sheet > equity

113618000

Quarters > 3 > cash Flow > net Income

-29163000

Quarters > 3 > cash Flow > depreciation

214000

Quarters > 3 > cash Flow > change In Working Capital

-8760000

Quarters > 3 > cash Flow > cash From Operations

-32046000

Quarters > 3 > cash Flow > capital Expenditures

60000

Quarters > 3 > cash Flow > cash From Investing

33183000

Quarters > 3 > cash Flow > cash From Financing

328000

Quarters > 3 > cash Flow > net Change In Cash

1465000

Quarters > 3 > ratios > PE

-0.5523043465687333

Quarters > 3 > ratios > PB

0.6831623618616769

Quarters > 3 > ratios > ROE

-25.667587882201765

Quarters > 3 > ratios > ROA

-19.734731855861952

Quarters > 3 > ratios > FCF

-32106000

Quarters > 3 > ratios > Piotroski FScore

0

Quarters > 3 > ratios > fcf Percent

-36.98847926267281

Quarters > 3 > health Score

33

Valuation > metrics > PE

-0.41331117310529847

Valuation > metrics > PB

1.757997478125

Valuation > final Score

80

Valuation > verdict

Fair

Profitability > metrics > ROE

-49.42857142857143

Profitability > metrics > ROA

-33.29123819832822

Profitability > final Score

15

Profitability > verdict

Weak

Risk > metrics > Debt Equity

0.8464955357142857

Risk > metrics > Interest Coverage

-55.22549019607843

Risk > final Score

-173

Risk > verdict

High

Liquidity > metrics > Current Ratio

6.085079132741743

Liquidity > metrics > Quick Ratio

6.085079132741743

Liquidity > final Score

100

Liquidity > verdict

Great

Prev Valuations > 0

80

Prev Valuations > 1

70

Prev Valuations > 2

70

Prev Profitabilities > 0

15

Prev Profitabilities > 1

15

Prev Profitabilities > 2

0

Prev Risks > 0

-203

Prev Risks > 1

-253

Prev Risks > 2

-227

Prev Liquidities > 0

100

Prev Liquidities > 1

100

Prev Liquidities > 2

100

Updated At

2025-12-14T00:13:19.580Z